DSIP Discovery: How a Sleep Peptide Was Found in Rabbit Blood in 1977

LynxLab · 24 October 2026 · 8 min read

How Schoenenberger and Monnier isolated delta sleep-inducing peptide from rabbit cerebral blood in 1977, the nine-residue sequence, and what later trials found.

Photo: Noah Silliman, Unsplash

Delta sleep-inducing peptide has one of the odder origin stories in peptide science. It was pulled out of the blood of sleeping rabbits in Basel, named for the brainwaves it produced, and then spent four decades failing to prove it was what its name said. The discovery paper is still worth reading, because it explains both why dsip was taken seriously and why the question it raised was never closed.

What Marcel Monnier was looking for

The idea that something in the blood carries sleep goes back to the early 1900s, when researchers reported that fluid taken from sleep-deprived dogs made rested dogs drowsy. The hunt for a humoral sleep factor was on, and many candidates were proposed over the following decades.

Marcel Monnier, a physiologist at the University of Basel, picked the problem up in the 1960s. His approach was mechanical. He put rabbits to sleep by stimulating the intralaminar thalamus with low-frequency current, then ran blood from the brain's venous drainage through a dialysis membrane and injected the dialysate into awake rabbits.

The 1964 report in Science, "Dialysis of sleep and waking factors in blood of the rabbit", is cited in the later discovery paper as the start of the programme. By 1972 Monnier's group had a purified "factor delta" fraction, named for the slow delta waves it provoked on the EEG. What they did not have was a molecule.

The 1977 isolation and the nine-residue sequence

Guido Schoenenberger, a biochemist in the surgical research department at Basel's Kantonsspital, supplied the chemistry. In March 1977 he and Monnier published "Characterization of a delta-electroencephalogram (-sleep)-inducing peptide" in the Proceedings of the National Academy of Sciences.

The paper reports a peptide isolated from the extracorporeal dialysate of rabbit cerebral venous blood, with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Nine residues, molecular weight 849. They named it delta sleep-inducing peptide, and the abbreviation stuck.

The test was unusually rigorous for the time. The team synthesised not only the nonapeptide but also five likely breakdown fragments, two analogues with amino acids swapped, and a related tripeptide.

All nine were infused into the cerebral ventricles of rabbits and the EEG was run through a Fourier transform on a Univac 1108 computer. The fragments and analogues did nothing. The synthetic dsip peptide did.

A fuller account appeared the same year in Pflügers Archiv, where the group reported a mean 35% increase in delta activity in both the neocortex and the limbic cortex, and noted that only the alpha-aspartyl form of the peptide was active, not the beta-isomer. The Pflügers Archiv paper also lists the dose: 6 nmol/kg in a cerebrospinal-fluid-like solution over three and a half minutes.

Why the name set expectations the data never met

The word "inducing" in the name is doing a lot of work. In the rabbit experiments the peptide increased delta-wave power on the EEG. That is not the same as sending an animal to sleep, and it was not the same as a sedative.

Markus Graf and Abba Kastin, who reviewed the field in Neuroscience and Biobehavioral Reviews in 1984, already described a U-shaped dose-response curve, a dependence on the time of infusion, and effects in cats that leaned towards REM sleep rather than delta sleep. They also noted that DSIP-like material had been detected by radioimmunoassay in the brain, in peripheral organs and in the plasma of several mammals.

A researcher wanting dsip for research in 2026 is therefore working with a compound whose defining property was always more modest than its name. The 1984 review listed effects on neurotransmitter levels, circadian and locomotor rhythms, hormone release and the behaviour of other drugs alongside the sleep EEG.

The human sleep trials of the 1980s

The first human work came from Dietrich Schneider-Helmert's sleep laboratory, again in Basel, working with Schoenenberger. In 1981 they reported on six middle-aged chronic insomniacs given 25 nmol/kg of synthetic DSIP intravenously. The paper described longer sleep with fewer interruptions and no daytime sedation, with the sleep-promoting effect only appearing in the second hour after injection.

In 1987 Schneider-Helmert published a larger placebo-controlled study of 14 chronic insomniacs treated for seven successive nights. He reported that night sleep improved with the first dose and further with repeated doses, that the effect carried over into the first placebo night afterwards, and that daytime alertness and performance rose.

Other laboratories did not reproduce this. An Italian group published a double-blind crossover trial in the same year, also at 25 nmol/kg over four nights, and concluded that the sleep changes were "of little clinical significance" because the differences from placebo were already present at baseline. A University of Amsterdam team recruited severe insomniacs through Dutch national newspapers for a double-blind study published in 1992 and reached the same verdict: administration for three consecutive days was of little therapeutic significance.

The split has a plausible explanation that nobody has tested. The Basel group injected slowly, over about four minutes, and considered the rate important. The negative studies did not single it out. Whether that accounts for the difference, or whether the Basel results were an artefact of small open-label designs, remains unknown.

Why no gene or receptor was ever found

The deepest problem with DSIP is not the mixed trial results. It is that nobody has ever found where it comes from.

Every known peptide hormone is cut from a larger precursor protein coded by a gene. For DSIP, no gene, no precursor and no receptor has ever been identified in any species. Vladimir Kovalzon and Tatyana Strekalova laid this out in a 2006 review in the Journal of Neurochemistry titled, accurately, "Delta sleep-inducing peptide (DSIP): a still unresolved riddle".

Their conclusions were blunt. The link between DSIP and sleep "has never been further characterized", and the hypothesis that it is a sleep factor is "extremely poorly documented and still weak". In their own rabbit and rat work, certain structural analogues of DSIP promoted slow-wave sleep while native DSIP itself did not.

Kovalzon and Strekalova proposed that the antibodies used in the 1980s were detecting a different, structurally similar peptide, which they called a DSIP-like peptide, and that this unknown molecule accounts for both the immunoreactivity and the biological effects. Twenty years on, that peptide has not been found either. Anyone comparing a buy dsip listing against the literature should know that the compound in the vial is the synthetic 1977 sequence, and that its natural counterpart is still hypothetical.

Where DSIP research stands in 2026

The peptide has not disappeared. Russian groups use a DSIP-based product called Deltaran and continue to publish animal work. A 2021 paper in Molecules reported that DSIP given to rats after an induced stroke improved recovery of motor function, and summarised two decades of Russian stress and neuroprotection studies. None of this has been replicated in a Western trial.

In the UK, DSIP has no marketing authorisation from the MHRA and is not a licensed medicine anywhere outside Russia. It is sold here for laboratory research only. LynxLab stocks dsip 5mg for research use at £13.95 a vial, tested to 99% purity with the lab report on the product page. The batch certificate of analysis is published alongside every product.

Researchers interested in the second half of the story, the stress, cortisol, pain and withdrawal studies that followed the sleep work, can read our companion piece on DSIP beyond sleep. For the sleep question itself, the honest summary is that the 1977 discovery was real, careful and reproducible in rabbits, and that everything after it is contested. Those searching for dsip in the UK are buying a well-characterised synthetic peptide with an unfinished biography.

Frequently asked questions

Who discovered DSIP?

Guido Schoenenberger and Marcel Monnier at the University of Basel, Switzerland. They published the isolation and sequence in the Proceedings of the National Academy of Sciences in March 1977, building on Monnier's sleep-dialysis experiments in rabbits that began in the 1960s.

What is the amino acid sequence of DSIP?

Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, a nine-residue peptide with a molecular weight of 849. The 1977 papers showed that breakdown fragments and swapped-residue analogues were inactive in rabbits, and that only the alpha-aspartyl isomer produced the delta EEG effect.

Does DSIP actually induce sleep?

In rabbits it increased delta-wave EEG activity by about 35% in the 1977 experiments. In humans, small Basel studies in the 1980s reported better sleep in insomniacs, but Italian and Dutch double-blind trials found changes of little clinical significance. A 2006 review concluded the sleep hypothesis is still weak.

Has a DSIP gene or receptor been found?

No. As of the 2006 Journal of Neurochemistry review, no gene, precursor protein or receptor for DSIP had been identified in any species, and that remains the case. Researchers have proposed that an unidentified DSIP-like peptide explains the antibody signals seen in tissue.

Is DSIP a licensed medicine?

Not in the UK, the EU or the United States. A DSIP-based product called Deltaran is used in Russia. In the UK the peptide is supplied for laboratory research only and has no MHRA marketing authorisation.

Sources

Research use only

DSIP from LynxLab

5mg vials from £13.95. ≥99% purity, lab report on the page. Same-day dispatch, UK stock.

Buy DSIP